MULTIVALVE : A Prospective Multicentre Study of Multiple and Mixed Valvular Heart Disease
ConditionValvular Heart Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFrench Cardiology Society
About this trial
Multiple and mixed valvular heart disease (MMVD) is a common condition in clinical practice. It corresponds to a combination of stenotic or leaky lesions on two or more heart valves (multiple valve disease), or a combination of stenotic and leaky lesions on the same valve (mixed valve disease). However, the management of their clinical, biological and cardiovascular imaging is not well established. Current European Society of Cardiology (ESC) recommendations primarily address the various valve diseases in isolation. This results in an absence of reliable recommendations for managing MMVD, with different approaches being adopted by care centres.
In order to address this knowledge gap regarding MMVD, it is crucial to assess its prevalence, the cardiovascular imaging methods employed and the management strategies, as well as to identify prognostic factors for the various combinations of valve disease.
The multicentre MMVD study will be a valuable resource as it will improve our understanding of the prognosis for patients with MMVD. It will highlight imaging and biological markers associated with the prognosis of different combinations of MMVD.
Eligibility criteria
Qualifiers
Age ≥18 years
The patient has been informed of the study and has not refused to participate.
An echocardiographic diagnosis of MMVD is defined as having at least two moderate to severe valvulopathies, as assessed by a cardiologist using transthoracic echocardiography (TTE), on one or more valves. This is in line with the recommendations of the ESC, the ASE, and expert opinion.
Disqualifiers
History of valve surgery or percutaneous valve intervention involving the valve in question.
A history of infective endocarditis, whether treated surgically or not, confirmed according to the modified Duke criteria.
Acute infective endocarditis at the time of evaluation for inclusion, confirmed according to the modified Duke criteria.
Complex congenital heart disease.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,000 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov